Form 4: Reviva Pharmaceuticals CFO Acquires Stock Options
SEC Form 4 Filing
Prabhu Narayan, CFO of Reviva Pharmaceuticals, reports the acquisition of stock options for 194,250 shares.
Summary
- Prabhu Narayan, the Chief Financial Officer of Reviva Pharmaceuticals Holdings, Inc., filed a Form 4.
- The form reports a transaction where Narayan acquired stock options to purchase 194,250 shares of common stock.
- The options were granted on February 13, 2025, with an exercise price of $1.80 per share.
- 80,938 of the shares subject to the option are immediately vested on the Grant Date.
- 89,043 shares subject to the option will vest in equal installments on the last day of each month from March 2025 to December 2026.
- 24,269 shares subject to the option will vest in equal installments on the last day of each month from January 2027 to December 2027.
- The options expire on February 12, 2035.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a key executive. It suggests confidence in the company's future, but doesn't provide any groundbreaking news.
Positives
- The grant of stock options to the CFO aligns his interests with those of the shareholders.
- The vesting schedule incentivizes long-term performance.
Future Outlook
NA
Industry Context
Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with shareholder value.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry, similar to companies like Amgen, Biogen, and Gilead Sciences.
- The vesting schedule is fairly standard, with a mix of immediate and time-based vesting to incentivize both short-term and long-term performance.
Stakeholder Impact
- Shareholders: The stock option grant aligns the CFO's interests with increasing shareholder value.
- Employees: The grant may have a positive impact on employee morale as it signals confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Grant Date of the stock options |
| 02/18/2025 | Date of signature of the Form 4 |
| 02/12/2035 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.